LEXINGTON, MA – March 5, 2015 Quanterix Corporation, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced that Myriad RBM, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ: MYGN), will use Quanterix…
LEXINGTON, MA – July 23, 2015 Quanterix Corporation, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced it was named a final winner of GE and the NFL’s Head Health Challenge I’s phase two grant. There were…
Quanterix Teams Up with Global Leaders to Establish a Groundbreaking Vision for Early Disease Detection, Prevention and Precision Drug Development to Revolutionize Healthcare
December 2, 2015
Quanterix announces the success of the company’s recent user conference entitled, “Proteins Powering NextGen Healthcare: San Francisco.”
March 8, 2016
Quanterix announces that Kevin Hrusovsky, Executive Chairman and CEO, will present at the Cowen and Company 36th Annual Health Care Conference.
October 18, 2016
Quanterix announces that it has been named the “Late Stage Leader” Buzz of BIO winner. As a winner of this award – which recognizes innovative companies that have raised more than $25 million as of July 1, 2016 – Quanterix will also be presenting at the 2016 BIO Investor Forum.
May 1, 2017
Kevin Hrusovsky, CEO and Executive Chairman at Quanterix, will join a distinguished panel of industry experts to discuss the state and future of precision cardiovascular medicine at the World Medical Innovation Forum. The panel is taking place Tuesday, May 2nd, from 2:00-2:50pm.
Quanterix Raises $8.5 Million in Private Financing Led by T. Rowe Price Associates; Also Appoints Dr. Marijn Dekkers to Company’s Board of Directors and Several Key Executives to Its Leadership Team
August 3, 2017
Additional capital to be used to develop new instruments, expand assay menu and globalize commercial channel